A citation-based method for searching scientific literature

Lola Rahib, Benjamin D Smith, Rhonda Aizenberg, Allison B Rosenzweig, Julie M Fleshman, Lynn M Matrisian. Cancer Res 2014
Times Cited: 3038







List of co-cited articles
386 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
23

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Thierry Conroy, Pascal Hammel, Mohamed Hebbar, Meher Ben Abdelghani, Alice C Wei, Jean-Luc Raoul, Laurence Choné, Eric Francois, Pascal Artru, James J Biagi,[...]. N Engl J Med 2018
676
16

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
16

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Thierry Conroy, Françoise Desseigne, Marc Ychou, Olivier Bouché, Rosine Guimbaud, Yves Bécouarn, Antoine Adenis, Jean-Luc Raoul, Sophie Gourgou-Bourgade, Christelle de la Fouchardière,[...]. N Engl J Med 2011
15

Genomic analyses identify molecular subtypes of pancreatic cancer.
Peter Bailey, David K Chang, Katia Nones, Amber L Johns, Ann-Marie Patch, Marie-Claude Gingras, David K Miller, Angelika N Christ, Tim J C Bruxner, Michael C Quinn,[...]. Nature 2016
14

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O'Reilly, David Cunningham, Jonathan Wadsley,[...]. Lancet 2017
771
12

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Daniel D Von Hoff, Thomas Ervin, Francis P Arena, E Gabriela Chiorean, Jeffrey Infante, Malcolm Moore, Thomas Seay, Sergei A Tjulandin, Wen Wee Ma, Mansoor N Saleh,[...]. N Engl J Med 2013
12

Pancreatic cancer.
Terumi Kamisawa, Laura D Wood, Takao Itoi, Kyoichi Takaori. Lancet 2016
10

Cancer Statistics, 2017.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2017
10

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
9

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
9

Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2018
8

Pancreatic cancer.
Jorg Kleeff, Murray Korc, Minoti Apte, Carlo La Vecchia, Colin D Johnson, Andrew V Biankin, Rachel E Neale, Margaret Tempero, David A Tuveson, Ralph H Hruban,[...]. Nat Rev Dis Primers 2016
602
8

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Helmut Oettle, Peter Neuhaus, Andreas Hochhaus, Jörg Thomas Hartmann, Klaus Gellert, Karsten Ridwelski, Marco Niedergethmann, Carl Zülke, Jörg Fahlke, Michael B Arning,[...]. JAMA 2013
884
7

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
H A Burris, M J Moore, J Andersen, M R Green, M L Rothenberg, M R Modiano, M C Cripps, R K Portenoy, A M Storniolo, P Tarassoff,[...]. J Clin Oncol 1997
7


Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Eric A Collisson, Anguraj Sadanandam, Peter Olson, William J Gibb, Morgan Truitt, Shenda Gu, Janine Cooc, Jennifer Weinkle, Grace E Kim, Lakshmi Jakkula,[...]. Nat Med 2011
785
7

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Agnieszka K Witkiewicz, Elizabeth A McMillan, Uthra Balaji, GuemHee Baek, Wan-Chi Lin, John Mansour, Mehri Mollaee, Kay-Uwe Wagner, Prasad Koduru, Adam Yopp,[...]. Nat Commun 2015
538
7

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Helmut Oettle, Stefan Post, Peter Neuhaus, Klaus Gellert, Jan Langrehr, Karsten Ridwelski, Harald Schramm, Joerg Fahlke, Carl Zuelke, Christof Burkart,[...]. JAMA 2007
6

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Malcolm J Moore, David Goldstein, John Hamm, Arie Figer, Joel R Hecht, Steven Gallinger, Heather J Au, Pawel Murawa, David Walde, Robert A Wolff,[...]. J Clin Oncol 2007
6

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.
Richard A Moffitt, Raoud Marayati, Elizabeth L Flate, Keith E Volmar, S Gabriela Herrera Loeza, Katherine A Hoadley, Naim U Rashid, Lindsay A Williams, Samuel C Eaton, Alexander H Chung,[...]. Nat Genet 2015
661
6

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
Siân Jones, Xiaosong Zhang, D Williams Parsons, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, Hirohiko Kamiyama, Antonio Jimeno,[...]. Science 2008
6

Pancreatic cancer.
Jonathan D Mizrahi, Rishi Surana, Juan W Valle, Rachna T Shroff. Lancet 2020
142
6

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.
Sonja Gillen, Tibor Schuster, Christian Meyer Zum Büschenfelde, Helmut Friess, Jörg Kleeff. PLoS Med 2010
897
5

Whole genomes redefine the mutational landscape of pancreatic cancer.
Nicola Waddell, Marina Pajic, Ann-Marie Patch, David K Chang, Karin S Kassahn, Peter Bailey, Amber L Johns, David Miller, Katia Nones, Kelly Quek,[...]. Nature 2015
5

Pancreatic adenocarcinoma.
David P Ryan, Theodore S Hong, Nabeel Bardeesy. N Engl J Med 2014
5

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.
Prashanth Rawla, Tagore Sunkara, Vinaya Gaduputi. World J Oncol 2019
427
5

Distant metastasis occurs late during the genetic evolution of pancreatic cancer.
Shinichi Yachida, Siân Jones, Ivana Bozic, Tibor Antal, Rebecca Leary, Baojin Fu, Mihoko Kamiyama, Ralph H Hruban, James R Eshleman, Martin A Nowak,[...]. Nature 2010
5

Pancreatic adenocarcinoma.
David P Ryan, Theodore S Hong, Nabeel Bardeesy. N Engl J Med 2014
234
5

Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma.
Junya Peng, Bao-Fa Sun, Chuan-Yuan Chen, Jia-Yi Zhou, Yu-Sheng Chen, Hao Chen, Lulu Liu, Dan Huang, Jialin Jiang, Guan-Shen Cui,[...]. Cell Res 2019
135
5

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
669
5

Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.
Janet E Murphy, Jennifer Y Wo, David P Ryan, Wenqing Jiang, Beow Y Yeap, Lorraine C Drapek, Lawrence S Blaszkowsky, Eunice L Kwak, Jill N Allen, Jeffrey W Clark,[...]. JAMA Oncol 2018
180
4

Pancreatic Cancer Surgery: The New R-status Counts.
Oliver Strobel, Thomas Hank, Ulf Hinz, Frank Bergmann, Lutz Schneider, Christoph Springfeld, Dirk Jäger, Peter Schirmacher, Thilo Hackert, Markus W Büchler. Ann Surg 2017
128
4

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Cristina R Ferrone, Giovanni Marchegiani, Theodore S Hong, David P Ryan, Vikram Deshpande, Erin I McDonnell, Francesco Sabbatino, Daniela Dias Santos, Jill N Allen, Lawrence S Blaszkowsky,[...]. Ann Surg 2015
436
4

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
4

Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Jin-Young Jang, Youngmin Han, Hongeun Lee, Sun-Whe Kim, Wooil Kwon, Kyung-Hun Lee, Do-Youn Oh, Eui Kyu Chie, Jeong Min Lee, Jin Seok Heo,[...]. Ann Surg 2018
179
4

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
4

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.
Davendra P S Sohal, Erin B Kennedy, Alok Khorana, Mehmet S Copur, Christopher H Crane, Ignacio Garrido-Laguna, Smitha Krishnamurthi, Cassadie Moravek, Eileen M O'Reilly, Philip A Philip,[...]. J Clin Oncol 2018
100
4

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.
Francesco Puleo, Rémy Nicolle, Yuna Blum, Jérôme Cros, Laetitia Marisa, Pieter Demetter, Eric Quertinmont, Magali Svrcek, Nabila Elarouci, Juan Iovanna,[...]. Gastroenterology 2018
126
4

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.
Andrew D Rhim, Paul E Oberstein, Dafydd H Thomas, Emily T Mirek, Carmine F Palermo, Stephen A Sastra, Erin N Dekleva, Tyler Saunders, Claudia P Becerra, Ian W Tattersall,[...]. Cancer Cell 2014
994
4

The pancreas cancer microenvironment.
Christine Feig, Aarthi Gopinathan, Albrecht Neesse, Derek S Chan, Natalie Cook, David A Tuveson. Clin Cancer Res 2012
709
4

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.
Daniel Öhlund, Abram Handly-Santana, Giulia Biffi, Ela Elyada, Ana S Almeida, Mariano Ponz-Sarvise, Vincenzo Corbo, Tobiloba E Oni, Stephen A Hearn, Eun Jung Lee,[...]. J Exp Med 2017
621
4

CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Werner Hartwig, Oliver Strobel, Ulf Hinz, Stefan Fritz, Thilo Hackert, Constanze Roth, Markus W Büchler, Jens Werner. Ann Surg Oncol 2013
136
3

Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.
T Hank, U Hinz, I Tarantino, J Kaiser, W Niesen, F Bergmann, T Hackert, M W Büchler, O Strobel. Br J Surg 2018
30
10

Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis.
Michael Tachezy, Florian Gebauer, Monika Janot, Waldemar Uhl, Alessandro Zerbi, Marco Montorsi, Julie Perinel, Mustapha Adham, Christos Dervenis, Christos Agalianos,[...]. Surgery 2016
56
5

Redefining the R1 resection in pancreatic cancer.
C S Verbeke, D Leitch, K V Menon, M J McMahon, P J Guillou, A Anthoney. Br J Surg 2006
363
3

Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.
M Wagner, C Redaelli, M Lietz, C A Seiler, H Friess, M W Büchler. Br J Surg 2004
625
3

Radical surgery of oligometastatic pancreatic cancer.
T Hackert, W Niesen, U Hinz, C Tjaden, O Strobel, A Ulrich, C W Michalski, M W Büchler. Eur J Surg Oncol 2017
82
3

Most pancreatic cancer resections are R1 resections.
Irene Esposito, Jörg Kleeff, Frank Bergmann, Caroline Reiser, Esther Herpel, Helmut Friess, Peter Schirmacher, Markus W Büchler. Ann Surg Oncol 2008
409
3

Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.
Thilo Hackert, Milena Sachsenmaier, Ulf Hinz, Lutz Schneider, Christoph W Michalski, Christoph Springfeld, Oliver Strobel, Dirk Jäger, Alexis Ulrich, Markus W Büchler. Ann Surg 2016
207
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.